
Mental health disorders proportion was 29.9 percent, an increase from 20.6 percent before head and neck cancer diagnosis, stated new study.
Using information from a large insurance claims database, this study examined how common mental health disorders were in patients with HNC and how they were associated with diagnosis and treatment.
Advertisement
‘Treatment for head and neck cancer (HNC) might cure the disease but it also can result in adverse effects such as disfigurement and speech difficulties, which can affect quality of life for patients. ’
Tweet it Now
Women and patients with a history of tobacco use and alcohol use were more likely to develop mental health disorders. The study may have underestimated how common mental health disorders were among the patients.
Authors: Neerav Goyal, M.D., M.P.H., Pennsylvania State University, Hershey, and coauthors
(doi:10.1001/jamaoto.2018.4512)
Editor's Note: The article includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Source: Eurekalert
Editor's Note: The article includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Source: Eurekalert
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News

Colorectal cancer can be lowered by up to 7% by increasing dietary consumption of folate rich foods like spinach, broccoli or taking folate supplements.

The effects and mechanisms of microRNA-451a (miR-451a), which hinders the progression of gemcitabine-resistant biliary tract cancers, are under study.

The blood test pinpointed 13 proteins capable of distinguishing between early and late stages of pancreatic cancer.

A fatty acid present in dairy products, beef, and lamb called trans-vaccenic acid enhances immune cells' capacity to combat cancers.

Trametinib plus dabrafenib combined therapy demonstrated a clear therapeutic benefit in children with BRAF-mutated low- and high-grade gliomas.